RAPT vs. CYBN, SGMT, RGLS, MCRB, SYRS, RNAC, INCR, RENB, PDSB, and IMAB
Should you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include Cybin (CYBN), Sagimet Biosciences (SGMT), Regulus Therapeutics (RGLS), Seres Therapeutics (MCRB), Syros Pharmaceuticals (SYRS), Cartesian Therapeutics (RNAC), InterCure (INCR), Renovaro (RENB), PDS Biotechnology (PDSB), and I-Mab (IMAB). These companies are all part of the "pharmaceutical preparations" industry.
Cybin (NYSE:CYBN) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.
17.9% of Cybin shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 6.6% of RAPT Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Cybin has higher earnings, but lower revenue than RAPT Therapeutics. Cybin is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cybin currently has a consensus price target of $5.00, indicating a potential upside of 1,351.38%. RAPT Therapeutics has a consensus price target of $24.67, indicating a potential upside of 516.67%. Given RAPT Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cybin is more favorable than RAPT Therapeutics.
In the previous week, Cybin had 5 more articles in the media than RAPT Therapeutics. MarketBeat recorded 12 mentions for Cybin and 7 mentions for RAPT Therapeutics. RAPT Therapeutics' average media sentiment score of 0.65 beat Cybin's score of -0.03 indicating that Cybin is being referred to more favorably in the media.
Cybin has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
Cybin's return on equity of -72.61% beat RAPT Therapeutics' return on equity.
RAPT Therapeutics received 87 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.
Summary
Cybin and RAPT Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get RAPT Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RAPT Therapeutics Competitors List
Related Companies and Tools
